-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Equity pledge is a normal financing guarantee behavior, which means that when the company needs cash, it can pledge stocks to the bank for stock trading and use the loan money to complete the project
.
Therefore, under normal circumstances, as far as the stock market is concerned, the release of the pledge is good
.
The author has learned that since October, many pharmaceutical companies have released news about the disqualification of their controlling shareholders
.
Shandong Pharmaceutical Glass’s controlling shareholder dissolves 7,318,500 shares.
Shandong Pharmaceutical Glass issued an announcement on October 13.
Release the pledge
.
The pledged shares released this time are 7,318,500 shares pledged to China Resources Shenzhen International Investment Trust Co.
, Ltd.
on April 27, 2020
.
Shandong Pharmaceutical Glass is mainly engaged in the research and development, production and sales of various medicinal glass packaging products
.
The 2021 mid-year report shows that the company’s main operating income was 1.
812 billion yuan, up 17.
98% year-on-year; net profit attributable to parent was 301 million yuan, up 14.
62% year-on-year; non-net profit was 289 million yuan, up 11.
78% year-on-year; debt ratio was 25.
9%, investment The income was RMB 2,137,700, the financial expenses were RMB 1,529,700, and the gross profit rate was 30.
39%
.
Zhendong Pharmaceutical’s controlling shareholder pledged 6.
88 million shares.
Zhendong Pharmaceutical announced on October 11 that the company’s controlling shareholder Zhendong Group released 6.
88 million shares from the pledge on September 30, 2021, accounting for 1.
79% of its shares and accounting for the company’s total share capital.
0.
67%
.
Zhendong Pharmaceutical is an enterprise mainly engaged in the research and development, production and sales of vitamins, mineral preparations, traditional Chinese medicines, innovative medicines and other products
.
The 2021 semi-annual report shows that the company achieved operating income of 2.
647 billion yuan in the first half of the year, a year-on-year increase of 34.
03%; net profit attributable to shareholders of listed companies was 221 million yuan, a year-on-year increase of 87.
44%
.
Dongcheng Pharmaceutical’s controlling shareholder releases 9.
45 million shares of pledge.
Dongcheng Pharmaceutical issued an announcement on the evening of October 7 stating that Dongyi Bio pledged 9.
45 million shares
.
According to the "Notice", as of September 30, 2021, Dongyi Bio holds approximately 125 million shares of Dongcheng Pharmaceutical, and has pledged approximately 24.
88 million shares.
The accumulated pledged shares account for 19.
92% of the total shares held.
Equity pledge risk Overall controllable, there is no risk of liquidation at present
.
The main business of Dongcheng Pharmaceutical is the nuclear medicine business segment, the bulk drug business segment and the preparation business segment
.
The 2021 semi-annual report shows that the company realized operating income of 1.
826 billion yuan from January to June 2021, a year-on-year increase of 10.
93%.
The net profit attributable to shareholders of listed companies was 155 million yuan, a year-on-year decrease of 29.
32%.
Earnings per share was 0.
1932 yuan
.
Yiling Pharmaceutical’s controlling shareholder dissolves 49 million shares.
Yiling Pharmaceutical issued an announcement on October 8.
The company received a notice from its controlling shareholder Yiling Pharmaceutical Technology on October 8, 2021 that Yiling Pharmaceutical Technology will hold the company.
Some of the shares of the company were released from the pledge
.
According to the data, Yiling Pharmaceutical focuses on the R&D pipeline of the Chinese medicine sector.
Under the guidance of innovative collateral disease theory, it focuses on the six areas with high incidence of cardiovascular and cerebrovascular diseases, diabetes, respiratory, tumor, neurology, and urinary drugs, and the large amount of drugs used in the market.
For major diseases, we have developed a series of patented Chinese medicines with independent intellectual property rights, forming a distinctive product layout advantage in the pharmaceutical industry
.
The 2021 semi-annual report shows that during the reporting period, the company achieved operating income of 5.
896 billion yuan, a year-on-year increase of 31.
41%; net profit attributable to shareholders of listed companies was 964 million yuan, a year-on-year increase of 34.
99%; non-recurring deductions attributable to shareholders of listed companies The net profit of profit and loss was 929 million yuan, a year-on-year increase of 34.
37%; the weighted average return on net assets was 10.
26%, an increase of 1.
62 percentage points from the same period last year
.
.
Therefore, under normal circumstances, as far as the stock market is concerned, the release of the pledge is good
.
The author has learned that since October, many pharmaceutical companies have released news about the disqualification of their controlling shareholders
.
Shandong Pharmaceutical Glass’s controlling shareholder dissolves 7,318,500 shares.
Shandong Pharmaceutical Glass issued an announcement on October 13.
Release the pledge
.
The pledged shares released this time are 7,318,500 shares pledged to China Resources Shenzhen International Investment Trust Co.
, Ltd.
on April 27, 2020
.
Shandong Pharmaceutical Glass is mainly engaged in the research and development, production and sales of various medicinal glass packaging products
.
The 2021 mid-year report shows that the company’s main operating income was 1.
812 billion yuan, up 17.
98% year-on-year; net profit attributable to parent was 301 million yuan, up 14.
62% year-on-year; non-net profit was 289 million yuan, up 11.
78% year-on-year; debt ratio was 25.
9%, investment The income was RMB 2,137,700, the financial expenses were RMB 1,529,700, and the gross profit rate was 30.
39%
.
Zhendong Pharmaceutical’s controlling shareholder pledged 6.
88 million shares.
Zhendong Pharmaceutical announced on October 11 that the company’s controlling shareholder Zhendong Group released 6.
88 million shares from the pledge on September 30, 2021, accounting for 1.
79% of its shares and accounting for the company’s total share capital.
0.
67%
.
Zhendong Pharmaceutical is an enterprise mainly engaged in the research and development, production and sales of vitamins, mineral preparations, traditional Chinese medicines, innovative medicines and other products
.
The 2021 semi-annual report shows that the company achieved operating income of 2.
647 billion yuan in the first half of the year, a year-on-year increase of 34.
03%; net profit attributable to shareholders of listed companies was 221 million yuan, a year-on-year increase of 87.
44%
.
Dongcheng Pharmaceutical’s controlling shareholder releases 9.
45 million shares of pledge.
Dongcheng Pharmaceutical issued an announcement on the evening of October 7 stating that Dongyi Bio pledged 9.
45 million shares
.
According to the "Notice", as of September 30, 2021, Dongyi Bio holds approximately 125 million shares of Dongcheng Pharmaceutical, and has pledged approximately 24.
88 million shares.
The accumulated pledged shares account for 19.
92% of the total shares held.
Equity pledge risk Overall controllable, there is no risk of liquidation at present
.
The main business of Dongcheng Pharmaceutical is the nuclear medicine business segment, the bulk drug business segment and the preparation business segment
.
The 2021 semi-annual report shows that the company realized operating income of 1.
826 billion yuan from January to June 2021, a year-on-year increase of 10.
93%.
The net profit attributable to shareholders of listed companies was 155 million yuan, a year-on-year decrease of 29.
32%.
Earnings per share was 0.
1932 yuan
.
Yiling Pharmaceutical’s controlling shareholder dissolves 49 million shares.
Yiling Pharmaceutical issued an announcement on October 8.
The company received a notice from its controlling shareholder Yiling Pharmaceutical Technology on October 8, 2021 that Yiling Pharmaceutical Technology will hold the company.
Some of the shares of the company were released from the pledge
.
According to the data, Yiling Pharmaceutical focuses on the R&D pipeline of the Chinese medicine sector.
Under the guidance of innovative collateral disease theory, it focuses on the six areas with high incidence of cardiovascular and cerebrovascular diseases, diabetes, respiratory, tumor, neurology, and urinary drugs, and the large amount of drugs used in the market.
For major diseases, we have developed a series of patented Chinese medicines with independent intellectual property rights, forming a distinctive product layout advantage in the pharmaceutical industry
.
The 2021 semi-annual report shows that during the reporting period, the company achieved operating income of 5.
896 billion yuan, a year-on-year increase of 31.
41%; net profit attributable to shareholders of listed companies was 964 million yuan, a year-on-year increase of 34.
99%; non-recurring deductions attributable to shareholders of listed companies The net profit of profit and loss was 929 million yuan, a year-on-year increase of 34.
37%; the weighted average return on net assets was 10.
26%, an increase of 1.
62 percentage points from the same period last year
.
